CSPC Pharmaceutical Group Limited (CSPCY)
USD 3.05
(-2.71%)
USD 3.05
(-2.71%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 15.19 Billion CNY | -2.17% |
| 2022 | 15.49 Billion CNY | 8.07% |
| 2021 | 14.34 Billion CNY | 13.55% |
| 2020 | 12.62 Billion CNY | 11.65% |
| 2019 | 11.31 Billion CNY | 37.37% |
| 2018 | 8.23 Billion HKD | 68.03% |
| 2017 | 4.9 Billion HKD | 49.55% |
| 2016 | 3.27 Billion HKD | 28.11% |
| 2015 | 2.55 Billion HKD | 27.28% |
| 2014 | 2 Billion HKD | 31.67% |
| 2013 | 1.52 Billion HKD | 81.94% |
| 2012 | 838.82 Million HKD | -6.15% |
| 2011 | 893.83 Million HKD | -16.35% |
| 2010 | 1.06 Billion HKD | 10.65% |
| 2009 | 965.61 Million HKD | 3.14% |
| 2008 | 936.19 Million HKD | 8.0% |
| 2007 | 866.82 Million HKD | 180.59% |
| 2006 | 308.92 Million HKD | 1.21% |
| 2005 | 305.23 Million HKD | -19.91% |
| 2004 | 381.12 Million HKD | 16.56% |
| 2003 | 326.98 Million HKD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.46 Billion CNY | 24.11% |
| 2024 Q2 | 3.49 Billion CNY | 0.0% |
| 2023 Q4 | 3.59 Billion CNY | -4.64% |
| 2023 Q2 | 4.02 Billion CNY | 6.51% |
| 2023 Q1 | 3.77 Billion CNY | 5.19% |
| 2023 FY | 15.16 Billion CNY | -2.17% |
| 2023 Q3 | 3.76 Billion CNY | -6.24% |
| 2022 Q3 | 4.29 Billion CNY | 18.89% |
| 2022 FY | 15.49 Billion CNY | 8.07% |
| 2022 Q1 | 3.99 Billion CNY | -16.8% |
| 2022 Q2 | 3.61 Billion CNY | -9.51% |
| 2022 Q4 | 3.58 Billion CNY | -16.51% |
| 2021 Q4 | 4.8 Billion CNY | 9.94% |
| 2021 FY | 14.34 Billion CNY | 13.55% |
| 2021 Q3 | 4.36 Billion CNY | 3.42% |
| 2021 Q1 | 4.05 Billion CNY | 46.04% |
| 2021 Q2 | 4.22 Billion CNY | 4.08% |
| 2020 Q1 | 3.37 Billion CNY | 2.8% |
| 2020 Q4 | 2.77 Billion CNY | -30.51% |
| 2020 FY | 12.62 Billion CNY | 11.65% |
| 2020 Q3 | 3.99 Billion CNY | 5.44% |
| 2020 Q2 | 3.79 Billion CNY | 12.26% |
| 2019 Q1 | 3.14 Billion CNY | 23.51% |
| 2019 Q3 | 3.17 Billion CNY | -0.35% |
| 2019 Q4 | 3.28 Billion CNY | 3.47% |
| 2019 FY | 11.31 Billion CNY | 37.37% |
| 2019 Q2 | 3.18 Billion CNY | 1.48% |
| 2018 Q1 | 2.35 Billion CNY | 22.01% |
| 2018 Q2 | 2.14 Billion CNY | -8.89% |
| 2018 Q3 | 2.28 Billion CNY | 6.34% |
| 2018 Q4 | 2.54 Billion CNY | 11.5% |
| 2018 FY | 8.23 Billion HKD | 68.03% |
| 2017 FY | 4.9 Billion HKD | 49.55% |
| 2017 Q4 | 1.92 Billion CNY | 28.06% |
| 2017 Q3 | 1.5 Billion CNY | 17.02% |
| 2017 Q2 | 1.28 Billion CNY | 10.49% |
| 2017 Q1 | 1.16 Billion CNY | 15.29% |
| 2016 Q3 | 917.59 Million CNY | 2.21% |
| 2016 Q4 | 1.01 Billion CNY | 10.11% |
| 2016 Q2 | 897.72 Million CNY | 9.6% |
| 2016 FY | 3.27 Billion HKD | 28.11% |
| 2016 Q1 | 819.07 Million CNY | 0.52% |
| 2015 Q4 | 814.8 Million CNY | 10.67% |
| 2015 FY | 2.55 Billion HKD | 27.28% |
| 2015 Q3 | 736.27 Million CNY | -5.96% |
| 2015 Q2 | 782.94 Million CNY | 8.97% |
| 2015 Q1 | 718.48 Million CNY | 8.27% |
| 2014 Q4 | 663.58 Million CNY | 5.7% |
| 2014 FY | 2 Billion HKD | 31.67% |
| 2014 Q1 | 614.74 Million CNY | 13.68% |
| 2014 Q2 | 605.38 Million CNY | -1.52% |
| 2014 Q3 | 627.79 Million CNY | 3.7% |
| 2013 Q4 | 540.76 Million CNY | 29.12% |
| 2013 FY | 1.52 Billion HKD | 81.94% |
| 2013 Q3 | 418.8 Million CNY | 16.98% |
| 2013 Q2 | 357.99 Million CNY | -27.72% |
| 2013 Q1 | 495.32 Million CNY | 0.0% |
| 2012 FY | 838.82 Million HKD | -6.15% |
| 2011 FY | 893.83 Million HKD | -16.35% |
| 2010 FY | 1.06 Billion HKD | 10.65% |
| 2009 FY | 965.61 Million HKD | 3.14% |
| 2008 FY | 936.19 Million HKD | 8.0% |
| 2007 FY | 866.82 Million HKD | 180.59% |
| 2006 FY | 308.92 Million HKD | 1.21% |
| 2005 FY | 305.23 Million HKD | -19.91% |
| 2004 FY | 381.12 Million HKD | 16.56% |
| 2003 FY | 326.98 Million HKD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | 48.625% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | 10.986% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | -607.773% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -29713.443% |
| Novartis AG | 24.87 Billion USD | 38.902% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 99.871% |